

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

SUPPLEMENTAL ANNOUNCEMENT

(I) DELAY IN PUBLICATION OF THE 2026 ANNUAL RESULTS; AND (II) CONTINUED SUSPENSION OF TRADING

Reference is made to the Company's announcements dated 22 September 2026 and 2 October 2026 (the "**Announcements**") in relation to, among other things, the delay in publication of the 2026 Annual Results. Capitalised terms used in the Announcements have the same meanings as those used herein.

SUPPLEMENTAL INFORMATION

In addition to the matters disclosed in the Announcements, the Company wishes to provide the following supplemental information:

The commencement and coordination of the annual audit for the year ended 30 June 2026 was delayed this year, as a result of unforeseeable absence of the finance manager of a major subsidiary located in the People's Republic of China (the "**PRC**"), who is responsible for preparing financial statements and handling banking matters. A family member of the PRC finance manager unfortunately underwent two urgent major surgeries between July and August 2026, and the PRC finance manager asked for personal leave for approximately two months. The PRC finance manager was unable to fully resume normal duties until mid-September due to her family matters. This unforeseeable circumstance directly affected the commencement and coordination of audit procedures. The other finance personnel in the PRC lacked familiarity with Hong Kong audit requirements, this also caused a delay in providing the information requested by the Auditor. Furthermore, this subsidiary is the sole revenue-generating entity of the Group for the year ended 30 June 2026.

In view of the above, the Auditor required additional time to complete the audit process and the Company is unable to publish the 2026 Annual Results on or before 30 September 2026, as required by the Rule 13.49(1) of the Listing Rules. The outstanding audit work primarily includes (i) review of valuation and significant accounting estimates; (ii) bank and audit confirmation procedures; and (iii) other audit completion procedures, such as audit testing for subsequent events, reviewing the consolidated financial statements and related disclosures.

The Company is working closely with Auditor to provide all requisite information and documents to complete the audit procedures as soon as possible. After discussion with Auditor, the Company now expects the 2026 Annual Results will be published by early November 2026.

This announcement is supplemental to and should be read in conjunction with the Announcements. Save and except as disclosed hereinabove, all the other information contained in the Announcements remains unchanged.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended since 9:00 a.m. on 2 October 2026 and will remain suspended pending the publication of the 2026 Annual Results.

The Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman

Hong Kong, 7 October 2026

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer), and three independent non-executive directors, namely Mr. Wong Po Keung, Ms. Xu Huiling and Mr. Wang Ziniu.